Should You Buy Neuphoria Therapeutics Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Neuphoria Therapeutics Inc. (NEUP) scores 5.2/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $3.78, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 4 of 5 CirclFi valuation models project upside for Neuphoria Therapeutics Inc. (NEUP) at $3.78 — the model consensus leans bullish, with a Quality Score of 5.2/10 and Value-Trap risk of 42/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Neuphoria Therapeutics Inc. (NEUP) in 2026?
What Is the Bull Case vs the Bear Case for Neuphoria Therapeutics Inc. (NEUP)?
| Bull case — $6.98 target (+84.6%) | Bear case — $3.01 target (-20.4%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $6.98 (+84.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Quality of Company (QOC) framework, Neuphoria Therapeutics Inc.'s score of 5.2/10 signals fundamental weaknesses that could undermine the investment thesis. |
| Industry tailwind: breakthrough therapy designations could provide meaningful support for Neuphoria Therapeutics Inc.'s revenue and margin trajectory in the Biotechnology space. | According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. |
| According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model sees the stock as overvalued with a fair value of $3.01 (-20.4%), suggesting that the market price embeds overly optimistic growth assumptions. | |
| According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +105.0% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. | |
| Industry headwind: reimbursement uncertainty represents a meaningful risk for Neuphoria Therapeutics Inc. and its Biotechnology peers. |
How Does NEUP Compare to Its Biotechnology Peers?
Valuation data pages: MREO · ABOS · ALDX · XBIT · ALMS · ORKA · BDRX · SPTX · IONS · EXEL · INCY
Which Other Stocks Score Like NEUP on Quality?
Closest companies to NEUP’s Quality of Company score of 5.2/10, across all industries.
- CIRX — CirTran Corporation (QOC 5.2) · analysis
- SNTL — Sentinel Holdings Ltd. (QOC 5.2) · analysis
- MBGL — Mobility Global, Inc. (QOC 5.2) · analysis
- APHP — American Picture House Corporation (QOC 5.2) · analysis
- SNDA — Sonida Senior Living, Inc. (QOC 5.2) · analysis
- BNAI — Brand Engagement Network, Inc. (QOC 5.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does NEUP Appear In?
So Is Neuphoria Therapeutics Inc. (NEUP) Worth Buying in 2026?
Neuphoria Therapeutics Inc. at $3.78 is a genuine coin-flip in our framework. The 1–1 bull-bear split across 5 models, +105.0% model spread, and median fair value of $3.81 (+0.9% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 5.2/10 adds additional caution to the mix.
These are quantitative model outputs, not investment recommendations. Neuphoria Therapeutics Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About NEUP Stock?
Should I buy NEUP stock right now?
Based on CirclFi's multi-model analysis, 4 of 5 models see upside for NEUP at $3.78. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.2/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Neuphoria Therapeutics Inc.?
Key risks include: an elevated Value Trap score of 42/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (5/13 active), reducing analytical confidence; wide model disagreement (132% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does NEUP compare to its competitors?
Among Biotechnology peers, NEUP holds a Quality Score of 5.2/10. Comparable companies include MREO (QOC 5.2), ABOS (QOC 5.1), ALDX (QOC 5.2). The relative ranking helps investors identify whether NEUP offers better fundamental quality than alternatives in the same sector.
Is NEUP a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NEUP's Quality Score of 5.2/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy NEUP at?
CirclFi does not provide target buy prices or price alerts. However, our 5 active models produce fair value estimates ranging from $3.01 to $6.98. At $3.78, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for NEUP.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad